Electra Therapeutics

Electra Therapeutics is a clinical-stage biotechnology company in South San Francisco, California, founded in 2018 and pioneering first-in-class antibody therapies directed at signal regulatory proteins (SIRP) for immunological diseases and cancer. Its lead candidate, ELA026 (ipsoprubart), is a monoclonal antibody targeting SIRP-alpha/beta1/gamma on myeloid cells and T lymphocytes to selectively deplete the pathological immune cells that drive the cytokine storm in secondary hemophagocytic lymphohistiocytosis (sHLH); it is in the pivotal SURPASS Phase 2/3 study. A second SIRP-targeted program, ELA822, is directed at activated T lymphocytes for immunology and inflammation indications. The company has raised roughly $267M from investors including OrbiMed, Nextech Invest, EQT Life Sciences and Westlake Village BioPartners. Electra publishes a corporate website, pipeline, publications, clinical-trial and news pages, but no public developer program, API documentation, or machine-readable API contract of any kind.

Electra Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Immunology.

Electra Therapeutics’ developer surface includes product news, engineering blog, and 12 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesImmunologyOncologyClinical TrialsAntibody TherapeuticsHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 11.5/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/electra-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfUse

TermsOfUse

Company 7

The organization behind the API

Website

Careers

News

Blog

BlogFeeds

LinkedIn

Investors

Investors

Scroll for all 7

Other 2

Properties that don't map to a standard resource type

Research

Research

Team

Team

Source (apis.yml)

aid: electra-therapeutics
name: Electra Therapeutics
image: https://electra-therapeutics.com/wp-content/uploads/2022/01/Electra_Logo_White_wOrange_Dot.png
description: Electra Therapeutics is a clinical-stage biotechnology company in South San Francisco, California, founded in
  2018 and pioneering first-in-class antibody therapies directed at signal regulatory proteins (SIRP) for immunological diseases
  and cancer. Its lead candidate, ELA026 (ipsoprubart), is a monoclonal antibody targeting SIRP-alpha/beta1/gamma on myeloid
  cells and T lymphocytes to selectively deplete the pathological immune cells that drive the cytokine storm in secondary
  hemophagocytic lymphohistiocytosis (sHLH); it is in the pivotal SURPASS Phase 2/3 study. A second SIRP-targeted program,
  ELA822, is directed at activated T lymphocytes for immunology and inflammation indications. The company has raised roughly
  $267M from investors including OrbiMed, Nextech Invest, EQT Life Sciences and Westlake Village BioPartners. Electra publishes
  a corporate website, pipeline, publications, clinical-trial and news pages, but no public developer program, API documentation,
  or machine-readable API contract of any kind.
url: https://raw.githubusercontent.com/api-evangelist/electra-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Oncology
- Clinical Trials
- Antibody Therapeutics
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/electra-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/electra-therapeutics-llms.txt
- type: Website
  url: https://electra-therapeutics.com/
- type: Research
  url: https://electra-therapeutics.com/publications/
- type: Team
  url: https://electra-therapeutics.com/leadership/
- type: Careers
  url: https://electra-therapeutics.com/career-opportunities/
- type: Contact
  url: https://electra-therapeutics.com/contact/
- type: News
  url: https://electra-therapeutics.com/news/
- type: Blog
  url: https://electra-therapeutics.com/news/
- type: BlogFeeds
  url: https://electra-therapeutics.com/news/feed/
- type: PrivacyPolicy
  url: https://electra-therapeutics.com/privacy-policy/
- type: TermsOfUse
  url: https://electra-therapeutics.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/electra-tx
- type: Investors
  url: https://forgeglobal.com/electra-therapeutics_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 3
  pass: local-v1